The FDA has lifted some restrictions on mifepristone. It should lift them all.
By Rachel Rebouché, Greer Donley, and David S. Cohen
December 22, 2021
Earlier this month the Food and Drug Administration (FDA) took the noteworthy step of removing a restriction on access to the drug mifepristone: Patients will no longer be required to collect the drug — the first of a two-drug regimen that induces abortion before 10 weeks of pregnancy — at a health care facility. The federal agency’s move appears to give a welcome boost to abortion access, but the FDA could and should have gone further.
When the FDA approved mifepristone in 2000, it dictated how the medication is prescribed and dispensed. The broad consensus among experts is that the FDA restriction on how patients could access the drug was unnecessary — mifepristone has a better safety record than penicillin and Viagra — and unique, given how other drugs of comparable risk are regulated.